Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...
After a brief cool-off last week, U.S. semiconductor and memory stocks are rallying in Tuesday morning trading, led by Micron, which traded above a $1 trillion market capitalization for the first time.
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
New Cancer Research Could Be a Massive Game Changer for Ozempic and Mounjaro
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly (LLY) will acquire three vaccine developers in all-cash deals with a combined value of up
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins
Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.
Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 […]
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion combined, the company told The Wall Street Journal. Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co. Curevo is developing a shingles vaccine that Lilly believes could be as effective as the current standard but with reduced side effects, said Daniel Skovronsky, Lilly’s chief scientific and product officer.
(Bloomberg) -- US equity futures extended gains and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on
These players are seeing exciting results in clinical trials.
LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.
The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.
Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with expectations ahead of further detail at the American Diabetes Association meeting. UBS...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Vanguard Dividend Appreciation Index Fund ETF Shares (NYSEARCA:VIG) is having a quieter year than its big-cap dividend-growth reputation suggests, with shares around $229 and a 5% year-to-date gain trailing the broader market. The 12-month picture is stronger at almost 17%, but the recent flattening tells you something important: VIG’s dividend-growth playbook is being squeezed ... VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line
The pharma giant is taking steps to expand its portfolio.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
